Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
Thumbnail

EMS response slower for cardiac arrest in low-income areas

It takes emergency medical services (EMS) almost four minutes longer to transport cardiac arrest patients from poor neighborhoods to the hospital versus those from high-income neighborhoods, according to a study of 2014 United States EMS data published in JAMA Network Open.

Prison populations more vulnerable to heart conditions

A new study by researchers at Yale and Drexel Universities explores the heart health problems associated with incarceration, in populations including those currently in prison and the released.

Thumbnail

Teaming Up to Treat Pulmonary Emboli: Clotbusters Illustrates Potential of Coordinated Response Programs

At one hospital, an aggressive treatment PE treatment program has dramatically reduced mortality.

Displaying 681 - 683 of 683

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup